Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells

Journal of Proteome Research

Volumn 7, Issue 5, 2008, Pages 1904-1915

  Qiu, Haibo ^a   Wang, Yinsheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Cell surface biotinylation; Immunocytochemistry; LC MS MS; Malignant melanoma; Membrane proteins; Quantitative proteomics; SILAC

Indexed keywords

AMINO ACID DERIVATIVE; CELL MEMBRANE PROTEIN; HISTONE; HISTONE H2B; TUMOR MARKER; ISOTOPE; MEMBRANE PROTEIN; TUMOR PROTEIN;

ARTICLE; BIOTINYLATION; CELL SURFACE; CONFOCAL MICROSCOPY; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; MELANOMA; METASTASIS; MOLECULAR GENETICS; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BIOTINYLATION; CELL LINE, TUMOR; CELL MEMBRANE; HUMANS; ISOTOPES; MELANOMA; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; NEOPLASM PROTEINS;

EID: 52049093719     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr700651b     Document Type: Article

References (78)

1. Wallin, E.; von Heijne, G. Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci. 1998, 7, 1029-1038.
2. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-730.
3. Santoni, V.; Molloy, M.; Rabilloud, T. Membrane proteins and proteomics: Un amour impossible. Electrophoresis 2000, 21, 1054-1070.
4. Wu, C. C.; Yates, I. R. The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 2003, 21, 262-267.
5. Wu, C. C.; MacCoss, M. J.; Howell, K. E.; Yates, J. R. A method for the comprehensive proteomic analysis of membrane proteins. Nat. Biotechnol. 2003, 21, 532-538.
6. Xiang, R.; Shi, Y.; Dillon, D. A.; Negin, B.; Horvath, C.; Wilkins, J. A. 2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474. J. Proteome Res. 2004, 3, 1278-1283.
7. Fischer, F.; Wolters, D.; Rogner, M.; Poetsch, A. Toward the complete membrane proteome-High coverage of integral membrane proteins through transmembrane peptide detection. Mol. Cell. Proteomics 2006, 5, 444-453.
8. Lohaus, C.; Nolte, A.; Bluggel, M.; Scheer, C.; Klose, J.; Gobom, J.; Schuller, A.; Wiebringhaus, T.; Meyer, H. E.; Marcus, K. Multidimensional chromatography: A powerful tool for the analysis of membrane proteins in mouse brain. J. Proteome Res. 2007, 6, 105-113.
9. Speers, A. E.; Wu, C. C. Proteomics of integral membrane proteins- theory and application. Chem. Rev. 2007, 107, 3687-3714.
10. Pasquali, C.; Fialka, I.; Huber, L. A. Subcellular fractionation, electromigration analysis and mapping of organelles. J. Chro-matogr., B 1999, 722, 89-102.
11. Zhao, Y. X.; Zhang, W.; Kho, Y. I.; Zhao, Y. M. Proteomic analysis of integral plasma membrane proteins. Anal. Chem. 2004, 76, 1817-1823.
12. Goshe, M. B.; Blonder, J.; Smith, R. D. Affinity labeling of highly hydrophobic integral membrane proteins for proteome-wide analysis. J. Proteome Res. 2003, 2, 153-161.
13. Chen, W. N. U.; Yu, L. R.; Strittmatter, E. F.; Thrall, B. D.; Camp, D. G.; Smith, R. D. Detection of in situ labeled cell surface proteins by mass spectrometry. Application to the membrane subproteome of human mammary epithelial cells. Proteomics 2003, 3, 1647-1651.
14. Hastie, C.; Saxton, M.; Akpan, A.; Cramer, R.; Masters, J. R.; Naaby-Hansen, S. Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 2005, 24, 5905-5913.
15. lang, J. H.; Hanash, S. Profiling of the cell surface proteome. Proteomics 2003, 3, 1947-1954.
16. Lee, S. J.; Kim, K. H.; Park,). S.; lung, J. W.; Kim, Y. H.; Kim, S. K.; Kim, W. S.; Goh, H. G.; Kim, S. H.; Yoo, J. S.; Kim, D. W.; Kim, K. P. Comparative analysis of cell surface proteins in chronic and acute leukemia cell lines. Biochem. Biophys. Res. Commun. 2007, 357, 620-626.
17. Mojica, W.; Sun, J. L. Plasma membrane protein identification by cell surface biotinylation and tandem mass spectrometry of clinical specimens. Mod. Pathol. 2006, 19, 162-162.
18. Nunomura, K.; Nagano, K.; Itagaki, C.; Taoka, M.; Okamura, N.; Yamauchi, Y.; Sugano, S.; Takahashi, N.; Izumi, T.; Isobe, T. Cell surface labeling and mass spectrometry reveal diversity of cell surface markers and signaling molecules expressed in undifferentiated mouse embryonic stem cells. Mol. Cell. Proteomics 2005, 4, 1968-1976.
19. Scheurer, S. B.; Rybak, I. N.; Roesli, C.; Brunisholz, R. A.; Potthast, F.; Schlapbach, R.; Neri, D.; Elia, G. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005, 5, 2718-2728.
20. Shin, B. K.; Wang, H.; Yim, A. M.; Le Naour, F.; Brichory, F.; Jang, J. H.; Zhao, R.; Puravs, E.; Tra, J.; Michael, C. W.; Misek, D. E.; Hanash, S. M. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 2003, 278, 7607-7616.
21. Sostaric, E.; Georgiou, A. S.; Wong, C. H.; Watson, P. F.; Holt, W. V.; Fazeli, A. Global profiling of surface plasma membrane proteome of oviductal epithelial cells. J. Proteome Res. 2006, 5, 3029-3037.
22. Tang, X. T.; Yi, W.; Munske, G. R.; Adhikari, D. P.; Zakharova, N. L.; Bruce, J. E. Profiling the membrane proteome of Shewanella oneidensis MR-1 with new affinity labeling probes. J. Proteome Res. 2007, 6, 724-734.
23. Zhang, W.; Zhou, G.; Zhao, Y. X.; White, M. A.; Zhao, Y. M. Affinity enrichment of plasma membrane for proteomics analysis. Electrophoresis 2003, 24, 2855-2863.
24. Zhao, Y. X.; Zhang, W.; White, M. A.; Zhao, Y. M. Capillary high-performance liquid chromatography/mass spectrometric analysis of proteins from affinity-purified plasma membrane. Anal. Chem. 2003, 75, 3751-3757.
25. Ong, S. E.; Mann, M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005, 1, 252-262.
26. Gygi, S. P.; Rist, B.; Gerber, S. A.; Turecek, F.; Gelb, M. H.; Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
27. Smolka, M. B.; Zhou, H. L.; Purkayastha, S.; Aebersold, R. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal. Biochem. 2001, 297, 25-31.
28. Ramus, C.; de Peredo, A. G.; Dahout, C.; Gallagher, M.; Garin, J. An optimized strategy for ICAT quantification of membrane proteins. Mol. Cell. Proteomics 2006, 5, 68-78.
29. Liang, X. Q.; Zhao, J.; Hajivandi, M.; Wu, R.; Tao, I.; Amshey, J. W.; Pope, R. M. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. J. Proteome Res. 2006, 5, 2632-2641.
30. Shi, Y.; Xiang, R.; Horvath, C.; Wilkins, J. A. Quantitative analysis of membrane proteins from breast cancer cell lines BT474 and MCF7 using multistep solid phase mass tagging and 2D LC/MS. J. Proteome Res. 2005, 4, 1427-1433.
31. Foster, L. J.; Zeemann, P. A.; Li, C; Mann, M.; Jensen, O. N.; Kassem, M. Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 2005, 23, 1367-1377.
32. Stockwin, L. H.; Blonder, J.; Bumke, M. A.; Lucas, D. A.; Chan, K. C.; Conrads, T. P.; Issaq, H. J.; Veenstra, T. D.; Newton, D. L.; Rybak, S. M. Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J. Proteome Res. 2006, 5, 2996-3007.
33. Bisle, B.; Schmidt, A.; Scheibe, B.; Klein, C.; Tebbe, A.; Kellermann, J.; Siedler, F.; Pfeiffer, F.; Lottspeich, F.; Oesterhelt, D. Quantitative profiling of the membrane proteome in a halophilic archaeon. Mol. Cell. Proteomics 2006, 5, 1543-1558.
34. Ong, S. E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
35. Simpson, R. J. Proteins and Proteomics: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2003.
36. McCarthy, J.; Hopwood, F.; Oxley, D.; Laver, M.; Castagna, A.; Righetti, P. G.; Williams, K.; Herbert, B. Carbamylation of proteins in 2-D electrophoresis-Myth or reality. J. Proteome Res. 2003, 2, 239-242.
37. Qiu, H.; Wang, Y. Probing adenosine nucleotide-binding proteins with an affinity-labeled nucleotide probe and mass spectrometry. Anal. Chem. 2007, 79, 5547-5556.
38. Loyet, K. M.; Ouyang, W. J.; Eaton, D. L.; Stults, J. T. Proteomic profiling of surface proteins on Thl and Th2 cells. J. Proteome Res. 2005, 4, 400-409.
39. Zhang, G.; Spellman, D. S.; Skolnik, E. Y.; Neubert, T. A. Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC). J. Proteome Res. 2006, 5, 581-588.
40. Multhoff, G.; Hightower, L. E. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones 1996, 1, 167-176.
41. Botzler, C.; Issels, R.; Multhoff, G. Heat-shock protein 72 cell-surface expression on human lung carcinoma cells in associated with an increased sensitivity to lysis mediated by adherent natural killer cells. Cancer Immunol. Immunother. 1996, 43, 226-230.
42. Van Holde, K. E. Chromatin; Springer-Verlag: New York, 1989.
43. Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997, 389, 251-260.
44. Ojcius, D. M.; Muller, S.; Hasselkus-Light, C. S.; Young, J. D.; Jiang, S. Plasma membrane-associated proteins with the ability to partially inhibit perforin-mediated lysis. Immunol. Lett. 1991, 28, 101-108.
45. Watson, K.; Gooderham, N. J.; Davies, D. S.; Edwards, R. J. Nucleosomes bind to cell surface proteoglycans. J. Biol. Chem. 1999, 274, 21707-21713.
46. Watson, K.; Edwards, R. J.; Shaunak, S.; Parmelee, D. C.; Sarraf, C.; Gooderham, N. J.; Davies, D. S. Extra-nuclear location of histones in activated human peripheral blood lymphocytes and cultured T-cells. Biochem. Pharmacol. 1995, 50, 299-309.
47. Hariton-Gazal, E.; Rosenbluh, J.; Graessmann, A.; Gilon, C.; Loyter, A. Direct translocation of histone molecules across cell membranes. J. Cell Sci. 2003, 116, 4577-4586.
48. Herren, T.; Burke, T. A.; Das, R.; Plow, E. F. Identification of histone H2B as a regulated plasminogen receptor. Biochemistry 2006, 45, 9463-9474.
49. Parseghian, M. H.; Luhrs, K. A. Beyond the walls of the nucleus: the role of histones in cellular signaling and innate immunity. Biochem. Cell Biol. 2006, 84, 589-604.
50. Ruth, M. C.; Old, W. M.; Emrick, M. A.; Meyer-Arendt, K.; Aveline- Wolf, L. D.; Pierce, K. G.; Mendoza, A. M.; Sevinsky, J. R.; Hamady, M.; Knight, R. D.; Resing, K. A.; Ahn, N. G. Analysis of membrane proteins from human chronic myelogenous leukemia cells: comparison of extraction methods for multidimensional LC-MS/MS. J. Proteome Res. 2006, 5, 709-719.
51. Shih, I. M. The role of CD146 (Mel-CAM) in biology and pathology. J. Pathol. 1999, 189, 4-11.
52. Denton, K. J.; Stretch, J. R.; Gatter, K. C; Harris, A. L. A study of adhesion molecules as markers of progression in malignant melanoma. J. Pathol. 1992, 167, 187-191.
53. Luca, M.; Hunt, B.; Bucana, C. D.; Johnson, J. P.; Fidler, I. J.; Bar-Eli, M. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res. 1993, 3, 35-41.
54. Xie, S.; Luca, M.; Huang, S.; Gutman, M.; Reich, R.; Johnson, J. P.; Bar-Eli, M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 1997, 57, 2295-2303.
55. Leslie, M. C.; Zhao, Y. J.; Lachman, L. B.; Hwu, P.; Wu, G. J.; Bar-Eli, M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther. 2007, 14, 316-323.
56. Abidi, S. M.; Saifullah, M. K.; Zafiropulos, M. D.; Kaput, C.; Bowen, M. A.; Cotton, C; Singer, N. G. CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis. J. Clin. Immunol. 2006, 26, 12-21.
57. Bowen, M. A.; Bajorath, J.; D'Egidio, M.; Whitney, G. S.; Palmer, D.; Kobarg, J.; Starling, G. C.; Siadak, A. W.; Aruffo, A. Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur. J. Immunol. 1997, 27, 1469-1478.
58. Aruffo, A.; Bowen, M. A.; Patel, D. D.; Haynes, B. F.; Starling, G. C.; Gebe, J. A.; Bajorath, J. CD6-ligand interactions: a paradigm for SRCR domain function. Immunol. Today 1997, 18, 498-504.
59. Burkhardt, M.; Mayordomo, E.; Winzer, K. J.; Fritzsche, F.; Gan- sukh, T.; Pahl, S.; Weichert, W.; Denkert, C.; Guski, H.; Dietel, M.; Kristiansen, G. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J. Clin. Pathol. 2006, 59, 403-409.
60. Jezierska, A.; Matysiak, W.; Motyl, T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med. Sci. Monit. 2006, 12, 263-273.
61. Klein, W. M.; Wu, B. P.; Zhao, S.; Wu, H.; Mein-Szanto, A. J.; Tahan, S. R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20, 102-107.
62. Kristiansen, G.; Pilarsky, G; Wissmann, C.; Stephan, C.; Weissbach, L.; Loy, V.; Loening, S.; Dietel, M.; Rosenthal, A. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003, 54, 34-43.
63. Lunter, P. C.; van Kilsdonk, J. W.; van Beek, H.; Cornelissen, I. M.; Bergers, M.; Willems, P. H.; van Muijen, G. N.; Swart, G. W. Activated leukocyte cell adhesion molecule (ALCAM/CD 166/ MEMD), a novel actor in invasive growth, controls matrix metal-loproteinase activity. Cancer Res. 2005, 65, 8801-8808.
64. van Kempen, L. C.; van den Oord, J. J.; van Muijen, G. N.; Weidle, U. H.; Bloemers, H. P.; Swart, G. W. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am. J. Pathol. 2000, 156, 769-774.
65. Degen, W. G.; van Kempen, L. C.; Gijzen, E. G.; van Groningen, J. J.; van Kooyk, Y.; Bloemers, H. P.; Swart, G. W. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am. J. Pathol. 1998, 152, 805-813.
66. Kersey, J. H.; LeBien, T. W.; Abramson, C. S.; Newman, R.; Sutherland, R.; Greaves, M. P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody. J. Exp. Med. 1981, 153, 726-731.
67. Si, Z.; Hersey, P. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int. J, Cancer 1993, 54, 37 43.
68. Zheng, R.; Yano, S.; Zhang, H.; Nakataki, E.; Tachibana, I.; Kawase, I.; Hayashi, S.; Sone, S. CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol. Res. 2005, 15, 365-372.
69. Huang, H.; Groth, J.; Sossey-Alaoui, K.; Hawthorn, L.; Beall, S.; Geradts, J. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin. Cancer Res. 2005, 11, 4357-4364.
70. Johnson, J. P. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 1999, 18, 345-357.
71. Saalbach, A.; Wetzel, A.; Haustein, U. F.; Sticherling, M.; Simon, J. C; Anderegg, U. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 2005, 24, 4710-4720.
72. Cavallaro, U.; Christofori, G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4, 118-132.
73. Kuphal, S.; Bauer, R.; Bosserhoff, A. K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005, 24, 195-222.
74. Vogel, C. L., Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
75. Natali, P. G.; Nicotra, M. R.; Digiesi, G.; Cavaliere, R.; Bigotti, A.; Trizio, D.; Segatto, O. Expression of gpl85HER-2 in human cutaneous melanoma: implications for experimental immuno- therapeutics. Int. J. Cancer. 1994, 56, 341-346.
76. Persons, D. L.; Arber, D. A.; Sosman, J. A.; Borelli, K. A.; Slovak, M. L. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Anticancer Res. 2000, 20, 1965-1968.
77. Eliopoulos, P.; Mohammed, M. Q.; Henry, K.; Retsas, S. Overex-pression of HER-2 in thick melanoma. Melanoma Res. 2002, 12, 139-145.
78. Kluger, H. M.; DiVito, K.; Berger, A. J.; Halaban, R.; Ariyan, S.; Camp, R. L.; Rimm, D. L. Her2/neu is not a commonly expressed therapeutic target in melanoma-a large cohort tissue microarray study. Melanoma Res. 2004, 14, 207-210.